Can a sound wave boost prostate cancer radiation precision?

NCT ID NCT07737457

Not yet recruiting Disease control Sponsor: London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's Source: ClinicalTrials.gov ↗

First seen Jul 30, 2026 · Last updated Jul 31, 2026 · Updated 1 time

Summary

This trial is testing whether using microultrasound to guide a radiation boost to cancerous spots inside the prostate can reduce side effects compared to standard radiation therapy. Men with intermediate-risk prostate cancer will receive stereotactic body radiation therapy (SBRT), with some getting an extra-high dose to tumor areas identified by microultrasound. The study aims to see if this targeted approach leads to fewer urinary problems while still controlling the cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: stereotactic body radiation therapy (SBRT) with or without a microultrasound-guided boost
What this could lead to: If successful, this approach could offer a more precise way to deliver radiation to prostate cancer, potentially reducing urinary side effects while maintaining effectiveness.
What could go wrong: This is a relatively early-stage trial with 112 participants, so results may not apply broadly. The microultrasound technique may not be as accurate as MRI for guiding the radiation boost.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for INTERMEDIATE RISK PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer prostate carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

PROSTATE CANCER

Contacts and locations

Locations

London Health Sciences Centre, Verspeeten Family Cancer Centre

London, Ontario, N6A 5W9, Canada

More trials for these conditions

Other studies related to the condition(s) this trial covers.